CHRS — Coherus Biosciences Balance Sheet
0.000.00%
Last trade - 00:00
- $251.35m
- $608.05m
- $257.24m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 178 | 541 | 417 | 192 | 118 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 142 | 157 | 123 | 110 | 261 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 343 | 767 | 602 | 381 | 476 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 16.5 | 20.1 | 16 | 14.4 | 11 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 409 | 842 | 679 | 481 | 630 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 115 | 146 | 165 | 139 | 332 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 304 | 561 | 582 | 618 | 823 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 105 | 281 | 97.7 | -137 | -193 |
Total Liabilities & Shareholders' Equity | 409 | 842 | 679 | 481 | 630 |
Total Common Shares Outstanding |